Document Detail


Brentuximab vedotin for the treatment of patients with hodgkin lymphoma.
MedLine Citation:
PMID:  24287065     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Hodgkin lymphoma (HL) is a relatively rare but highly curable human cancer. Because very few patients relapse and will require subsequent therapy, new drug development for HL has not been seen as a high priority by the pharmaceutical industry. Brentuximab vedotin, an antibody-drug conjugate that targets CD30 receptors, became the first drug to be approved by regulatory agencies for the treatment of HL in more than 30 years. This review summarizes the current and future directions of incorporating brentuximab vedotin in the management of patients with HL.
Authors:
Anas Younes
Related Documents :
25114505 - Pustular drug eruption due to panax notoginseng saponins.
24637185 - Assessment of postoperative changes in antihypertensive drug consumption in patients wi...
24532805 - G-749, a novel flt3 kinase inhibitor can overcome drug resistance for the treatment of ...
17300885 - Study of the extent of ocular absorption of acetazolamide from a developed niosomal for...
19443325 - Advertising of otc products in a nigerian urban setting: content analysis for indicatio...
24219855 - Novel self-assembly graft copolymers as carriers for anti-inflammatory drug delivery.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hematology/oncology clinics of North America     Volume:  28     ISSN:  1558-1977     ISO Abbreviation:  Hematol. Oncol. Clin. North Am.     Publication Date:  2014 Feb 
Date Detail:
Created Date:  2013-11-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709473     Medline TA:  Hematol Oncol Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  27-32     Citation Subset:  IM    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Affiliation:
Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. Electronic address: younesa@mskcc.org.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.
Next Document:  Combination chemoradiotherapy in early hodgkin lymphoma.